HomeAI · summaries
Storia in 3 fonti
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - NovoCure (NASDAQ:NVCR)
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Novocure’s electric fields therapy fails key glioblastoma study
Novocure's Optune Gio fails Phase 3 TRIDENT trial in newly diagnosed glioblastoma; overall survival nearly identical in early-use vs. approved arm. Shares drop 17%.
- ·
benzinga.com
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - NovoCure (NASDAQ:NVCR)
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.
